Six-month and 12-month outcomes in eyes with HRVO, compared with eyes with BRVO or CRVO
| HRVO | BRVO | P value (vs HRVO) | CRVO | P value (vs HRVO) | |
| Eyes, n | 79 | 590 | 344 | ||
| VA (letters) | |||||
| VA baseline, mean (SD) | 53.8 (17.7) | 59.4 (14.9) | 0.009 | 51.9 (18.7) | 0.40 |
| VA 6 months, mean (SD) | 69.9 (13.7) | 69.8 (14) | 0.96 | 60.7 (21.6) | <0.001 |
| VA 12 months, mean (SD) | 70.2 (15.3) | 70.8 (14) | 0.74 | 60.4 (23) | <0.001 |
| Change in VA (letters) | |||||
| ΔVA 6 months, mean (95% CI) | 16.1 (12.6 to 19.6) | 10.4 (9.3 to 11.5) | 0.003 | 8.8 (6.6 to 11.1) | <0.001 |
| ΔVA 12 months, mean (95% CI) | 16.4 (13.1 to 19.7) | 11.4 (10.2 to 12.6) | 0.006 | 8.5 (6.1 to 10.9) | <0.001 |
| Adjusted ΔVA 12 months, mean (95% CI) | 15.6 (11.9 to 19.3) | 13.2 (11.1 to 15.2) | 0.19 | 5.9 (3.6 to 8.3) | <0.001 |
| Gained ≥15 letters, % | 49 | 38 | 0.07 | 40 | 0.17 |
| Lost ≥15 letters, % | 1 | 3 | 0.50 | 13 | <0.001 |
| >70 letters, baseline/12 months, % | 24/68 | 32/68 | 0.15/1.0 | 21/45 | 0.54/<0.001 |
| ≤35 letters, baseline/12 months, % | 20/3 | 9 /3 | 0.007/1.0 | 22/16 | 0.88/<0.001 |
| Central subfield thickness (μm) | |||||
| CST baseline, mean (SD) | 550 (186) | 482 (159) | 0.004 | 630 (223) | 0.002 |
| CST 6 months, mean (SD) | 332 (112) | 342 (115) | 0.45 | 402 (213) | <0.001 |
| CST 12 months, mean (SD) | 319 (124) | 330 (105) | 0.31 | 371 (181) | 0.001 |
| Change in CST (μm) | |||||
| Δ CST 6 months, mean (95% CI) | −214 (−257 to –172) | −141 (−154 to –127) | 0.003 | −229 (−258 to –200) | 0.60 |
| Δ CST 12 months, mean (95% CI) | −231 (−277 to –184) | −151 (−166 to –137) | 0.003 | −259 (−287 to –231) | 0.33 |
| Adjusted Δ CST 12 months, mean (95% CI) | −218 (−253 to –183) | −204 (−224 to –184) | 0.42 | −173 (−195 to –150) | 0.019 |
| Treatment and visits | |||||
| Injections, median (Q1, Q3)* | 8 (6, 10) | 8 (5, 9) | 1.0 | 8 (5, 10) | 1.0 |
| Visits, median (Q1, Q3)* | 9 (9, 11) | 10 (8, 12) | 0.38 | 11 (8, 13) | 0.12 |
| Suspension of treatment, n (%)† | 12 (15) | 96 (16) | 1.0 | 41 (12) | 0.45 |
| Never became inactive in 12 months, n (%) | 12 (15) | 174 (29) | 0.007 | 85 (25) | 0.07 |
| VEGF switchers, n (%) | 11 (14) | 81 (14) | 1.00 | 36 (10) | 0.43 |
| Steroid switchers, n (%) | 1 (1) | 38 (6) | 0.07 | 20 (6) | 0.15 |
| Non-completion of 12 months, n (%) | 9 (11) | 100 (17) | 0.26 | 58 (17) | 0.30 |
Significant differences between HRVO vs BRVO and HRVO vs CRVO are in bold (p<0.05).
Adjusted, using analysis of covariance controlling for first treatment age and baseline VA or CST as fixed effects and nesting within patients (both eyes) or the same practice as random effects.
*Calculated only in completers receiving VEGF monotherapy throughout with Generalised Poisson models used to generate p values.
†Periods >180 days containing recorded visits and no treatment.
BRVO, branch RVO; CRVO, central retinal vein occlusion; CST, central subfield thickness; HRVO, hemiretinal vein occlusion; VA, visual acuity; VEGF, vascular endothelial growth factor.